Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Junko Tauchi"'
Autor:
Junko Tauchi, Yasushi Miyazawa, Sadamoto Zenda, Kaoru Endo, Takumi Kawaguchi, Shunji Koya, Masafumi Ikeda, Masako Shomura
Publikováno v:
Kanzo. 62:601-612
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b63abb8b18fa4243171419aca51cf1a
https://doi.org/10.2957/kanzo.62.601
https://doi.org/10.2957/kanzo.62.601
Autor:
Koki Morishita, Hidetaka Suzuki, Junko Tauchi, Misaki K Takeno, Shota Yamaguchi, Kanae Inoue, Tomonao Taira, Hiroki Eguchi, Kei Okumura, Taro Shibuki, Tomoyuki Satake, Kazuo Watanabe, Hiroshi Imaoka, Mitsuhito Sasaki, Shuichi Mitsunaga, Toshikatsu Kawasaki, Masafumi Ikeda
Publikováno v:
Journal of Clinical Oncology. 41:529-529
529 Background: Proteinuria is a well-known lenvatinib (LEN)-associated adverse event. The standard management of proteinuria includes measurement of the urinary protein/creatinine ratio (UPCR) in patients with a qualitative result for proteinuria of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77647a13655614e88e4718ff0dc784fe
https://doi.org/10.1200/jco.2023.41.4_suppl.529
https://doi.org/10.1200/jco.2023.41.4_suppl.529
Autor:
Kanako Mamishin, Kenji Kawasumi, Junko Tauchi, Masaki Tanaka, Asumi Kaneko, Yoshihiro Iwamoto, Reiko Matsui, Masahito Yonemura, Toshikathu Kawasaki
Publikováno v:
Annals of Oncology. 33:S544
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2427aeaf4ecfa588980722bd23283903
https://doi.org/10.1016/j.annonc.2022.05.516
https://doi.org/10.1016/j.annonc.2022.05.516
Autor:
Miyuki Uoi, Junko Tauchi, Kaoru Koshiba, Daisuke Hisamatsu, Atsushi Miyada, Haruna Kameoka, Shinya Takada, Takuya Hiromasa, Reiko Matsui, Ken Ohashi, Toshikatsu Kawasaki
Publikováno v:
Annals of Oncology. 33:S505
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fae3a3ce27301015ee45c81265e165c6
https://doi.org/10.1016/j.annonc.2022.05.194
https://doi.org/10.1016/j.annonc.2022.05.194
Autor:
Koki Morishita, Kohei Hayashi, Junko Tauchi, Misaki K Takeno, Hidetaka Suzuki, Masafumi Ikeda
Publikováno v:
Journal of Clinical Oncology. 38:507-507
507 Background: The REFLECT trial demonstrated that lenvatinib is non-inferior to sorafenib for first-line treatment of unresectable hepatocellular carcinoma (uHCC). However, no comparison of the frequency of adverse events (AEs) requiring interventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb36cd05c373fb4f925adae69cc9c9a4
https://doi.org/10.1200/jco.2020.38.4_suppl.507
https://doi.org/10.1200/jco.2020.38.4_suppl.507
Autor:
Mitsuhito Sasaki, Hideaki Takahashi, Izumi Ohno, Ken Ohashi, Gen Kimura, Yusuke Hashimoto, Taro Shibuki, Kumiko Umemoto, Junko Tauchi, Hiroshi Imaoka, Akira Shinohara, Toshikatsu Kawasaki, Kazuo Watanabe, Shuichi Mitsunaga, Masafumi Ikeda
Publikováno v:
Journal of Clinical Oncology. 37:337-337
337 Background: Diabetes mellitus (DM) and hyperglycemia have been widely considered to be associated with the risk of pancreatic cancer. However, the aim of this study was to evaluate the relationship between glycemic control and the efficacy or saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccdb189a1e007c27f6e5e778762283f6
https://doi.org/10.1200/jco.2019.37.4_suppl.337
https://doi.org/10.1200/jco.2019.37.4_suppl.337